A promising response to osimertinib in a patient with erlotinib-resistant lung adenocarcinoma with an uncommon EGFR mutation

Most patients with non-small cell lung cancer with common epidermal growth factor receptor (EGFR) mutations respond dramatically to EGFR tyrosine kinase inhibitors (TKIs), but data are limited on the response of tumours with uncommon mutations. We present the case of a 68-year-old man with stage IV...

Descripción completa

Detalles Bibliográficos
Autores principales: Niwa, Hideyuki, Nakahara, Yoshiro, Sasaki, Jiichiro, Masuda, Noriyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Case Reports 2018
Materias:
Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5990104/
https://www.ncbi.nlm.nih.gov/pubmed/29866661
http://dx.doi.org/10.1136/bcr-2017-219770

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5990104/
https://www.ncbi.nlm.nih.gov/pubmed/29866661
http://dx.doi.org/10.1136/bcr-2017-219770

Ejemplares similares